PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Adherence and Persistence After Switching Warfarin to Direct Oral Anticoagulants

vitamin K antagonistwarfarindirect oral anticoagulantsDOACapixabanrivaroxabandabigatranadherencepersistenceproportion of days coveredatrial fibrillationvenous thromboembolismanticoagulation switchingsystematic reviewanticoagulation stewardship Anticoagulation / Hematology

Background Information

Switching to DOACs? Adherence high, but persistence varies.

Switching from vitamin K antagonists (VKAs) to direct oral anticoagulants (DOACs) poses adherence and persistence challenges that impact treatment efficacy. Objective adherence rates after switching were generally high (76% to 97.5% achieving PDC ≥ 80%), though persistence varied widely (54% to 94%). Although adherence rates were high, variability in persistence suggests a need for standardized evaluation and adherence support after switching anticoagulants. Adherence is generally high when switching from VKAs to DOACs, but persistence varies, necessitating standardized evaluations.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Alaqab A, Alfaqeeh M, Hashim R, Mustafa M, Hamad A, Abu-Rmeileh NME, Abdulah R, Alfian SD

Citation: Alaqab A, Alfaqeeh M, Hashim R, et al. Medication adherence and treatment persistence following switching from vitamin K antagonists to direct oral anticoagulants: a systematic review. BMC cardiovascular disorders. 2026;26(1). doi:10.1186/s12872-026-06398-0

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.